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Original StudieS
Background: Neonatal meningitis is an important cause of morbidity in sub-
Saharan Africa and requires urgent empiric treatment with parenteral adminis-
tered antibiotics. Here we describe the etiology, antimicrobial susceptibility and 
suitability of the World Health Organization first-line recommended antibiotics 
(penicillin and gentamicin) for bacterial meningitis in young infants in Malawi.
Methods: We reviewed all cerebrospinal fluid samples received from 
infants ≤2 months of age with clinically suspected meningitis between 
January 1, 2002, and December 31, 2008, at the Queen Elizabeth Central 
Hospital in Blantyre, Malawi.
Results: We identified 259 culture-positive isolates from 259 infants ≤2 months 
of age. Sixty isolates were from neonates ≤7 days old, in whom the most com-
mon pathogens were Group B Streptococcus (27/60; 45.0%), Streptococcus 
pneumoniae (13/60; 21.7%) and nontyphoidal Salmonella enterica (7/60; 
11.7%). One hundred and ninety one isolates were from young infants who were 
>7 days and ≤2 months of age. In this group, the most common isolates were S. 
pneumoniae (80/191; 41.9%), Group B  Streptococcus (38/191; 19.9%) and non-
typhoidal Salmonella enterica (34/191; 17.8%). More isolates were susceptible 
to ceftriaxone than to the combination of penicillin and gentamicin (218/220; 
99.1% vs. 202/220; 91.8%, Fisher’s exact test P = 0.006). In particular, Gram-
negative isolates were significantly more susceptible to ceftriaxone than to gen-
tamicin (72/74; 97.3% vs. 63/74; 85.1%, Fisher’s exact test P = 0.020). Penicillin 
and gentamicin provided less coverage for Gram-negative than  Gram-positive 
isolates (74/86; 86.0% vs. 155/163; 95.1%, χ2 = 6.24, P = 0.012).
Conclusions: In view of these results, the World Health Organization rec-
ommendations for empiric penicillin and gentamicin for suspected neonatal 
meningitis should be reevaluated.
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An estimated 3.6 million neonatal deaths occurred worldwide in 2008, one-third of which were in Africa.1 Of these deaths, 17% 
were associated with sepsis.1 Although the exact burden of neonatal 
bacterial meningitis in Africa remains unknown, it represents an 
important cause of morbidity and mortality. A recent Kenyan study 
reported that 3–6% of all hospital admissions <59 days old were 
due to meningitis, with case fatality ratios of 26% in the first week 
of life and 18% between 7 and 59 days of age.2
Studies into neonatal meningitis in sub-Saharan Africa have 
reported a wide range of pathogens that vary both between and within 
countries. Streptococcus pneumoniae, Group B Streptococcus (GBS), 
Escherichia coli and nontyphoidal Salmonella species appear to pre-
dominate in East Africa.3–10 In West Africa, S. pneumoniae, E. coli and 
Salmonella species remain common, but a greater role is also seen for 
Staphylococcus aureus.11–15 In Southern Africa, GBS, E. coli and Sal-
monella species predominate, with a lesser role for S. pneumoniae.16–20
The range of pathogens within sub-Saharan Africa provides a 
major challenge to global antibiotic guidelines, particularly as treatment 
is required urgently. The World Health Organization (WHO) has out-
lined recommendations for empirical antimicrobial treatment for men-
ingitis in neonates and young infants <2 months of age (summarized in 
Supplemental Digital Content 1, http://links.lww.com/INF/B777).21–28
The WHO Pocket Book of Hospital Care for Children pro-
vides the most comprehensive guidance and is intended for use in 
secondary level health care. It recommends either benzylpenicillin/
ampicillin with gentamicin or ceftriaxone/cefotaxime if available as 
first-line treatment of meningitis in infants <2 months of age.25 Other 
WHO guidance suggests a third generation cephalosporin if there is 
no improvement after 48 hours.22,23 The country-specific appropriate-
ness for these guidelines can only be judged with knowledge of local 
etiologic organisms and their antimicrobial susceptibility patterns.
Previous etiologic studies of neonatal meningitis have 
included populations of differing ages. Some have included neo-
nates <30 days,4,8–10,12,13,15,16,18 young infants <60 days7 or <90 
days3,5,11 of age and others have described their population simply as 
neonates.6,14,17 To ensure our results were as relevant as possible to 
WHO guidance, we elected to include all young infants ≤60 days in 
an audit of bacterial meningitis in the Queen Elizabeth Central Hos-
pital (QECH) in Blantyre from 2002 to 2008 to determine the etiol-
ogy and pathogen resistance patterns and therefore evaluate the suit-
ability of WHO recommendations for first-line antibiotic therapy.
MATERIALS AND METHODS
Setting
QECH in Blantyre, Malawi is a large teaching, referral and 
district general hospital serving a population of approximately 
1  million and admitting around 25,000 children per year. Sick or 
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premature babies born in hospital are cared for in a separate ward 
from those born outside the hospital. There is no provision for 
mechanical ventilation, total parenteral nutrition or central venous 
lines. During the study, benzyl penicillin (50,000 units or 30 mg/kg 
3 or 4 times daily) and gentamicin (6 mg/kg/d) were first-line anti-
biotic therapy for meningitis in young infants ≤2 months of age 
in accordance with WHO guidelines.25 Antibiotic therapy may be 
changed in light of cerebrospinal fluid sample (CSF) culture and 
susceptibility results, which typically become available after 48 
hours. It should be remembered that QECH is fortunate to benefit 
from bacterial culture facilities that are not available in many other 
hospitals in the region.
Identification of Patients
All CSF from young infants ≤60 days of age with suspected 
meningitis received between January 1, 2002, and December 31, 2008, 
were reviewed. Demographic data were retrieved from laboratory and 
ward admission books. No infants in the inborn hospital nursery were 
>60 days of age. Outcome data and HIV status were not available.
Organism Identification and Speciation
All diagnostic testing and quality control was performed 
in the Malawi Liverpool Wellcome Trust Programme laboratories 
as part of routine clinical surveillance.29,30 CSF (1–2 mL) was ana-
lyzed by Gram’s stain if the white blood cell count was >10/mm3. 
All samples were cultured on sheep blood and chocolate agar for 
48 hours under aerobic and microaerophilic (candle jar) conditions. 
Bacteria were identified using standard methods as previously 
described.31 The laboratory participates in internationally recog-
nized quality control programs.
Susceptibility Testing
Antibiotic susceptibilities of the bacterial isolates were deter-
mined on all isolates by disc testing (Oxoid, Hampshire, United 
 Kingdom) and zone size measurement using the British Society for 
Antimicrobial Chemotherapy sensitivity method for direct cultures.32
Duplicated Samples
When repeat isolates were obtained from an infant within 
28 days of age, these were considered part of the same meningitis 
episode and were excluded. If >28 days had passed, this was con-
sidered a separate episode.
Organisms Excluded
The following organisms were considered contaminants 
and excluded from analysis: Bacillus spp., Diptheroids, Micro-
coccus spp. and any Streptococcus spp. (other than S. pneumo-
niae, Group A, B or D streptococci). Although Staphylococcus 
 epidermidis/coagulase-negative staphylococci may represent 
pathogens in  well-resourced neonatal intensive care settings, 
these were considered to be contaminants in our setting because 
care at QECH does not include central venous access or other 
invasive procedures. Isolates that were recorded only as “Coli-
form spp.” were also excluded, because we were unable to identify 
them to a species level.
Analysis
Data were collected and coded in Excel 2007 (Microsoft 
Corporation, Redmond, WA). Double data entry was performed. 
Statistical analyses were performed using STATA SE/11.0 (Stata-
Corp LP, College Station, TX). χ2 test was used where at least 80% 
of cells had an expected frequency of 5 or more, otherwise Fisher’s 
exact test was used.
Ethics
Ethical approval was not required as this was a retrospective 
audit of unlinked laboratory data.
RESULTS
Between January 1, 2002, and December 31, 2008 (inclu-
sive), 259 pathogens were isolated from 259 young infants. Of these 
infants, 60 (23.2%) were ≤7 days (mean: 5.4 days, median: 6.5 days, 
interquartile range: 4–7 days) and 191 (73.7%) were >7 days and 
≤2 months (mean: 28.4 days, median: 21 days, interquartile range: 
TABLE 1. Frequency of CSF Isolates by Age Group N (%).
Isolate ≤7 days >7 days ≤2 months Age unknown All ages
Gram-positive organisms
  Streptococcus pneumoniae 13 (21.7) 80 (41.9) 2 (25) 95 (36.7)
  Group B Streptococcus 27 (45.0) 38 (19.9) 3 (37.5) 68 (26.3)
  Group D Streptococcus 1 (1.7) 0 (0) 1 (12.5) 2 (0.8)
  S. aureus 0 (0) 3 (1.6) 0 (0) 3 (1.2)
  Group A Streptococcus 0 (0) 3 (1.6) 0 (0) 3 (1.2)
Gram-negative organisms
  S. enterica serovar Typhimurium 7 (11.7) 28 (14.7) 1 (12.5) 36 (13.9)
  S. enterica serovar Enteritidis 0 (0) 3 (1.6) 0 (0) 3 (1.2)
  Salmonella spp. 0 (0) 3 (1.6) 0 (0) 3 (1.2)
  H. influenzae type b 1 (1.7) 14 (7.3) 0 (0) 15 (5.8)
  H. influenzae–untyped 0 (0) 3 (1.6) 0 (0) 3 (1.2)
  E. coli 3 (5.0) 5 (2.6) 0 (0) 8 (3.1)
  E. cloacae 3 (5.0) 2 (1.1) 0 (0) 5 (1.9)
  Enterobacter agglomerans 0 (0) 1 (0.5) 0 (0) 1 (0.4)
  Enterobacter spp. 1 (1.7) 0 (0) 0 (0) 1 (0.4)
  Klebsiella pneumoniae 3 (5.0) 1 (0.5) 0 (0) 4 (1.5)
  Klebsiella spp. 0 (0) 0 (0) 1 (12.5) 1 (0.4)
  Pseudomonas aeruginosa 1 (1.7) 1 (0.5) 0 (0) 2 (0.8)
  Pseudomonas spp. 0 (0) 1 (0.5) 0 (0) 1 (0.4)
  Neisseria meningitides 0 (0) 2 (1.1) 0 (0) 2 (0.8)
  Acinetobacter lwoffii 0 (0) 1 (0.5) 0 (0) 1 (0.4)
  Morganella morganii 0 (0) 1 (0.5) 0 (0) 1 (0.4)
  Serratia oderfera 0 (0) 1 (0.5) 0 (0) 1 (0.4)
Total 60 191 8 259
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14–30 days) of age. Eight (3.1%) were admitted as “neonates” to 
the dedicated neonatal ward but their exact ages were not recorded. 
Isolates from this last group were included in the overall analysis 
of pathogens and susceptibility patterns, but excluded from age-
specific analyses (Table 1).
Across all age groups, 171/259 (66.0%) of isolates were 
Gram-positive and 88/259 (34.0 %) were Gram-negative. Overall, 
the commonest pathogens were S. pneumoniae in 95/259 (36.7%), 
GBS in 68/259 (26.3%), nontyphoidal Salmonella enterica (NTS) 
in 42/259 (16.2%) and Haemophilus influenzae type b (Hib) in 
15/259 (5.8%, Table 1).
In neonates ≤7 days, GBS was the most common organism 
found (27/60; 45.0%), followed by S. pneumoniae (13/60; 21.7%) and 
NTS (7/60; 11.7%). For young infants >7 days to ≤2 months of age, the 
most frequent isolate was S. pneumoniae (80/191; 41.9%), followed by 
GBS (38/191; 19.9%) and NTS in 34 of 191 (17.8%, Table 1).
Antimicrobial Susceptibility
In vitro isolate susceptibility to 9 antibiotics (penicillin, 
erythromycin, ampicillin, chloramphenicol, gentamicin, cotrimox-
azole, tetracycline, ciprofloxacin and ceftriaxone) is summarized in 
Table 2 (full data in Supplemental Digital Content 2, http://links.
lww.com/INF/B778). Not all isolates were tested against all antibi-
otics, in particular, 10 isolates were not tested against either penicil-
lin or gentamicin and 33 were not tested against ceftriaxone.
Overall, 229/249 (92.0%) of isolates tested showed in vitro 
susceptibility to the first-line combination of penicillin and gen-
tamicin (Table 2). Gram-positive isolates were significantly more 
likely to be susceptible than Gram-negative isolates (155/163; 
95.1% vs. 74/86; 86.0%, χ2 = 6.24, P = 0.012). Of the 226 iso-
lates tested against ceftriaxone, 224 (99.1%) were susceptible 
(Table 2). A subset of 220 isolates from the 226 was tested against 
both a first-line antibiotic and ceftriaxone. These isolates were 
significantly more susceptible to ceftriaxone than to the com-
bination of penicillin and gentamicin (n = 218/220; 99.1% vs. 
n = 202/220; 91.8%, Fisher’s exact test P = 0.006). Gram-positive 
isolates were all susceptible in vitro to ceftriaxone (n = 151); 
however, of the 162 tested against penicillin, 153 (94.4%) were 
susceptible (Table 2). A subset of 145 Gram-positive isolates were 
tested against both penicillin and ceftriaxone, with 139 of 145 
(95.9%) susceptible to penicillin and all 145 (100%) to ceftri-
axone. Of 92 S. pneumoniae isolates tested against penicillin, 6 
(6.5%) had intermediate resistance (detected by disc testing only), 
whereas all 92 (100%) of the isolates tested against ceftriaxone 
were susceptible (Table 2).
Gram-negative isolates were also significantly more sus-
ceptible to ceftriaxone than to first-line antibiotics. Eighty six 
Gram-negative isolates were tested against gentamicin, of which 
74 (86.0%) were susceptible, compared with 73 of 75 (97.3%) 
which were susceptible to ceftriaxone (Table 2). A subset of 74 
 Gram-negative isolates were tested against both gentamicin and 
ceftriaxone, and 63 of 74 (85.1%) were susceptible to gentamicin 
while 72 of 74 (97.3%) were susceptible to ceftriaxone (Fisher’s 
exact test P = 0.020).
All NTS isolates were tested against gentamicin and 37 
of 42 (88.1%) were susceptible. Of these isolates, 33 were tested 
against ceftriaxone and showed universal susceptibility (Table 2). 
Among those 33 isolates susceptible to ceftriaxone, 5 were resistant 
to gentamicin.
Only 2 isolates were resistant to ceftriaxone: Klebsiella pneu-
moniae and Enterobacter cloacae, isolated from 4- and 5-day-old 
neonates, respectively. These 2 isolates were also resistant to gen-
tamicin, but showed in vitro susceptibility to ciprofloxacin. Both 
isolates were identified in 2007, towards the end of the study period.
Although numbers were small, no significant trend in annual 
resistance patterns was found amongst isolates to the combination 
of penicillin and gentamicin (χ2 for trend, P = 0.291, Supplemental 
Digital Content 3, http://links.lww.com/INF/B779).
DISCUSSION
CSF Isolates
Our findings are similar to those of a previous study 
of neonatal sepsis ≤30 days of age in the same unit in Blantyre 
(1996–2001).9 This earlier study examined neonatal meningitis 
(n = 202) as a subset of neonatal sepsis (n = 784), but did not ana-
lyze CSF isolates further by age group. The authors reported GBS 
as the most common CSF isolate ≤30 days of age (60/202; 29.7%), 
followed by S. pneumoniae (47/202; 23.3%) and NTS (33/202; 
16.3%) but used a cut off of 30 days (favoring GBS) as opposed 
to 60 days in our study. Analysis of our data by age group revealed 
GBS was the commonest pathogen in neonates ≤7 days and 
S. pneumoniae in those >7 days but ≤2 months of age. Therefore, 
our results may not represent a true change in isolate frequency, but 
are more likely due to the inclusion of older infants in our study.
TABLE 2. In Vitro Antibiotic Susceptibility by CSF Isolate
Total isolates Penicillin Erythromycin Gentamicin Ceftriaxone Penicillin and gentamicin
Gram-positive organisms
  Streptococcus pneumoniae 95 86/92 (93) 93/93 (100) 0/2 (0) 91//91 (100) 86/92 (93)
  Group B Streptococcus 68 63/64 (98) 57/65 (88) 0/9 (0) 55/55 (100) 63/65 (97)
  Group A and Group D Streptococci 5 3/3 (100) 2/4 (50) 1/1 (100) 4/4 (100) 3/3 (100)
  S. aureus 3 1/3 (33) 3/3 (100) 2/2 (100) 1/1 (100) 3/3 (100)
Gram-negative organisms
  Nontyphoidal Salmonella 42 NT NT 37/42 (88) 33/33 (100) 37/42 (88)
  Haemophilus influenzae 18 NT NT 17/18 (94) 18/18 (100) 17/18 (94)
  Escherichia coli 8 NT NT 7/8 (88) 7/7 (100) 7/8 (88)
  Enterobacter spp. 7 NT NT 6/7 (86) 6/7 (86) 6/7 (86)
  Klebsiella spp. 5 NT NT 2/3 (67) 3/4 (75) 2/3 (67)
  Pseudomonas spp. 3 NT NT 1/3 (33) 1/1 (100) 1/3 (33)
  Other Gram-negatives 5 2/2 (100) 1/1 (100) 4/5 (80) 5/5 (100) 4/5 (80)
Number of susceptible isolates / number of 
isolates tested (percentage susceptible)
155/164 (95) 156/166 (94) 77/100 (77) 224/226 (99) 229/249 (92)
Nontyphoidal Salmonella, S. enertica serovar Enteritidis, S.enertica serovar Typhimurium or other Salmonella spp (not S. enterica serovar Typhi).
Other Gram-negatives,A. lwoffii, N. meningitides, M. morganii and S. oderfera.
Penicillin and gentamicin, isolate showed in vitro susceptibility to at least 1 of the combination of penicillin and gentamicin.
a/b (%), number susceptible/number tested (percentage susceptible). NT, Not tested.
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S. pneumoniae
S. pneumoniae was the major CSF pathogen in 36.7% of 
infants ≤2 months of age in this study, which is consistent with reports 
from East Africa3,5,7–10 and West Africa.11,12 S. pneumoniae resistance 
to penicillin is therefore of particular interest. In a recent review of 
invasive pneumococcal disease across all age groups (>3 months, 
n = 4445) penicillin resistance was reported to be stable at ≈10% over 
a decade.33 In our study, resistance to penicillin was 6.5% (6/92).
S. pneumoniae isolates in our study were universally suscep-
tible to ceftriaxone. No ceftriaxone resistance amongst S. pneumo-
niae isolates has been reported in this setting since the antibiotic’s 
introduction.33 However, a recent study from our setting did report 
an increase in minimum inhibitory concentration (from 0.0016 to 
0.125 mg/mL), suggesting S. pneumoniae isolates are becoming 
less susceptible to ceftriaxone.33
S. pneumoniae resistance to ceftriaxone may hasten with 
increasing use of this antibiotic. However, although penicillin use 
has been widespread in our setting over a long period, resistance 
has been fairly static over the past decade.33 Ongoing surveillance 
is therefore critical to identify resistance if it emerges. Molecular 
tools that may predict this emergence are currently under develop-
ment in this and other laboratories.
S. pneumoniae was the most common CSF isolate year on 
year (Table 3), underlining the importance of pneumococcal immu-
nization. The 13-valent pneumococcal conjugate vaccine was intro-
duced into the Malawian extended program for immunization in 
November 2011. It is hoped that herd immunity will protect the 
unimmunized population of young infants ≤2 months of age. The 
impact of pneumococcal vaccination on neonatal meningitis will be 
an important topic for surveillance in the coming years.
Group B Streptococcus
GBS was the leading cause of meningitis (45%) in neonates 
≤7 days and is emerging as an important cause of neonatal men-
ingitis in sub-Saharan Africa.6,8–10,16–18,34 GBS infections may be 
under-represented in community-born infants as the disease can be 
rapidly fatal and infants may die before reaching a health center.19
As GBS is vertically acquired from the maternal genital 
tract, maternal vaccination against the pathogen is attractive. How-
ever, as serotypes differ between countries, efforts to produce a 
globally effective vaccine are necessary. The successful genomic 
sequencing of GBS may have provided global candidate antigens35 
and a phase II vaccine study has just been completed in Malawi 
and another is in progress in South Africa (National Clinical Trial 
numbers NCT01412801and NCT01193920, respectively).
Nontyphoidal Salmonella
NTS was the most common Gram-negative organism 
responsible for meningitis and NTS neonatal meningitis has been 
reported in Malawi,8,9 Kenya5,7 and Niger.12 Fecal-oral transmission 
may put neonates at particularly high risk of invasive NTS infec-
tions due to relative achlorhydria and a reduction in gastric acids 
by frequent milk feeds.36 Clinical implications are serious, with a 
reported case fatality rate of 64–89%.8,9
Among the NTS isolates, 5/42 (11.9%) were resistant to 
gentamicin but there was universal susceptibility to ceftriaxone. 
Encouragingly, gentamicin resistance at QECH has decreased from 
55% (1996–1998)37 to 47% (1996–2001)9 and now 11.9%. How-
ever, doubts remain as to the suitability of gentamicin to treat NTS 
meningitis due to poor intracellular and blood-brain barrier pen-
etration.38
H. influenzae Type b
In our study, Hib was responsible for only 5.8% of menin-
gitis in neonates and young infants, which may be a consequence 
of recent vaccination introduction. Hib conjugate vaccine was 
introduced into the Malawian immunization schedule in February 
2002 (first dose at 2 months). A subsequent review of Hib menin-
gitis between 2 months and 15 years in QECH showed a mean of 
53.2 annual cases between 1997 and 2002, which decreased to 9.7 
between 2003 and 2009.39 In our study, Hib annual incidence fell 
from 6 cases in 2003 to 1 case per year between 2005 and 2008 
(Table 3), which suggests a herd immunity effect amongst unvac-
cinated infants ≤2 months of age.
Antimicrobial Susceptibility
First-line Antibiotic Susceptibility—Penicillin  
and Gentamicin
In this study, 92.0% (229/249 tested) of all isolates showed 
in vitro susceptibility to either penicillin or gentamicin. There-
fore, in this setting, WHO first-line antibiotics provide adequate 
empirical treatment for cases of suspected neonatal meningitis. 
However, these antibiotics provided significantly lower coverage 
for  Gram-negative than Gram-positive isolates (74/86; 86.0% vs. 
155/163; 95.1%, χ2 = 6.24, P = 0.012). Although WHO first-line 
antibiotics appear appropriate for meningitis in young infants in 
Blantyre where Gram-positive isolates predominate, they may not 
provide sufficient cover in settings where Gram-negative isolates 
have a larger role.
The combination of penicillin and gentamicin is cheap and 
widely available but requires 4 injections a day for at least 14 days; 
a minimum of 56 injections. In addition, gentamicin has a narrow 
therapeutic index and without the ability to measure therapeutic 
drug levels, the risks of ototoxicity and nephrotoxicity may be 
increased and/or therapeutic levels may not be attained.
A study in Kilifi, Kenya investigated the suitability of once 
daily gentamicin dosing in neonates in a setting similar to ours 
where routine therapeutic drug monitoring was not possible.40 The 
authors reported that 72-hour peak gentamicin levels were below the 
target of 4 μg/mL in 12% of neonates (potentially  subtherapeutic) 
and 96-hour trough levels were above the target of 1 μg/mL in 24% 
of patients (potentially toxic). This study also reported possible 
gentamicin-related nephrotoxicity in 1% of patients.
TABLE 3. Frequency of CSF Isolates by Year 
2002 2003 2004 2005 2006 2007 2008 Total Mean SD
Gram-positive organisms 22 31 24 35 20 24 15 171 24.4 6.7
Gram-negative organisms 14 22 11 9 11 14 7 88 12.6 4.9
S. pneumoniae 11 17 17 15 11 16 8 95 13.6 3.6
Group B Streptococcus 9 14 6 17 9 7 6 68 9.7 4.2
Nontyphoidal Salmonella 8 11 6 5 3 6 3 42 6.0 2.8
H. influenzae type b 3 6 2 1 1 1 1 15 2.1 1.9
Total isolates 36 53 35 44 31 38 22 259 37.0 9.8
Mean, arithmetic mean; SD, standard deviation.
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First-line Antibiotic Susceptibility—Ceftriaxone
Ceftriaxone has been available in the pediatric unit at QECH 
since 2001, although not for neonatal use. Its use has become 
more widespread since 2007 and in 2009, it was introduced as 
the  second-line antibiotic for neonatal meningitis. Ceftriaxone 
has good CSF penetrance41 and is given once daily, reducing pres-
sure on nursing staff. These factors are of particular importance in 
resource-poor settings.
In vitro susceptibility to ceftriaxone was 99.1% (224/226) 
and was significantly higher than for penicillin and gentamicin. 
The difference in susceptibility was particularly marked for 
 Gram-negative isolates. Our data shows only 2 cases of ceftriaxone 
resistance in neonatal meningitis involving a Klebsiella pneumo-
niae and an E. cloacae isolate. Emerging resistance to third gen-
eration cephalosporins is of particular concern in resource limited 
settings. For example, only 72% of Gram-negative blood culture 
isolates showed susceptibility to cefotaxime in Kenyan infants of 
the same age group.7 A recent study of Enterobacteriaceae in blood 
cultures from all age groups in QECH (n = 1191) identified 19 cef-
triaxone-resistant isolates, 10 of which showed  extended-spectrum 
β-lactamases (ESBL) phenotyopes.42 These were predominantly 
isolated from pediatric patients and the authors advised that 
increased use of cephalosporins was likely to result in a rapid ESBL 
expansion.42 Although ESBL genotyping was not available for our 
study, the presence of ceftriaxone-resistant Gram-negative organ-
isms in the absence of widely available alternative antibiotics is 
cause for considerable concern.
Questions remain regarding the safety of ceftriaxone use 
in neonates, including precipitation with calcium containing com-
pounds,43 biliary sludging44 and the displacement of albumin caus-
ing kernicterus.45 In vitro susceptibilities to antibiotics may not 
translate into good outcomes. A prospective randomized controlled 
trial to investigate the outcome of neonatal meningitis when treated 
with penicillin and gentamicin compared with a third generation 
cephalosporin and the safety of ceftriaxone in neonates is currently 
underway in Malawi (NCT01247909).
As a single center study, generalization of these results 
must be made with caution. This study was hospital based and 
may underrepresent early neonatal meningitis if babies born at 
home who died before attending the hospital. There was also no 
reliable way of distinguishing between community-acquired and 
 hospital-acquired infections.
CONCLUSION
Ceftriaxone provides significantly better in vitro cover-
age than the WHO-recommended combination of penicillin and 
gentamicin in meningitis in young infants in Blantyre, Malawi 
where Gram positive isolates predominate. This gap in suscepti-
bility may be even higher in settings where Gram-negative iso-
lates have a larger role. Ceftriaxone’s once daily dosing schedule 
also reduces pressure on nursing staff but resistance is emerging 
among  Gram-negative isolates and the safety profile of ceftriaxone 
in neonates is yet to be fully confirmed. In view of these results, 
the WHO recommendations of empirical penicillin and gentamicin 
for suspected neonatal meningitis should be reevaluated. This is 
particularly important for those settings where the prevalence of 
gentamicin resistant Gram-negative meningitis is high.
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